Merck: disappointing data in lung cancer
(CercleFinance.com) - Merck reports disappointing data from the two phase III trials LEAP-006 and LEAP-008, evaluating its blockbuster Keytruda, in combination with Eisai's Lenvima, in patients with certain types of metastatic non-small cell lung cancer.
In the final analysis of the LEAP-006 study, there was no improvement in overall survival (OS) in patients treated with this combination plus chemotherapy compared with Keytruda alone plus chemotherapy.
Likewise, in the final analysis of study LEAP-008, there was no improvement in OS in patients treated with Keytruda plus Lenvima compared with docetaxel, a current second-line standard of care option.
Copyright (c) 2023 CercleFinance.com. All rights reserved.